Enhanced immunogenicity of a bivalent nicotine vaccine
Introduction
Nicotine is the principal addictive component of tobacco smoke [1]. Vaccination against nicotine is a potential means of modifying or attenuating nicotine's addictive effects [2], [3]. Vaccination of rats with a suitable nicotine immunogen elicits the production of nicotine-specific antibodies which bind nicotine in serum and extracellular fluid, reduce the concentration of unbound nicotine, reduce or slow nicotine distribution to the brain [4], [5], [6], [7], and attenuate a variety of nicotine-induced behaviors in rats including locomotor activation [8], nicotine discrimination [9], and the acquisition, maintenance and reinstatement of nicotine self administration [10], [11]. The effects of immunization on nicotine pharmacokinetics in rats are a function of both the serum NicAb concentration and antibody affinity for nicotine. Close correlations have been found between the serum NicAb concentration and the percent of nicotine bound in serum, the concentration of unbound nicotine in serum, and the distribution of nicotine to brain [5], [12], [13]. Recent studies also show a correlation between the serum antibody concentration and a behavioral outcome, locomotor sensitization to nicotine (unpublished data). Three nicotine vaccines are in Phases II–III clinical trials as adjuncts for smoking cessation and have shown preliminary evidence of efficacy. In each of these clinical trials, efficacy has been closely related to the serum antibody concentration or titer in that increased smoking cessation rates were observed in only those subjects with the highest serum NicAb levels [4], [14], [15], [16], [17](C. Bunce, personal communication). These highly congruent animal and human data clearly demonstrate the need to achieve high serum NicAb concentrations in order to maximize the efficacy of vaccination for treating tobacco dependence.
Two challenges have emerged from clinical trials regarding the generation of high antibody concentrations from nicotine vaccines. First, the mean serum NicAb concentrations reported have been modest, 32 ug/ml in one trial [14], which is considerably lower than typical levels of 180–250 ug/ml in rats vaccinated with the same immunogen [5], [18]. This difference may be due in part to the ability to use Freund's adjuvant in rats, while alum was used in humans. Second, considerable variability in serum antibody concentrations has occurred following vaccination against nicotine; a 30-fold range in one study, from a high of 100 µg/ml to less than10 µg/ml [14]. Although only limited data have been published, these challenges appear to be common to all three nicotine vaccines currently under clinical investigation [14], [15](C. Bunce, personal communication). As a result, only a minority of vaccinated subjects have achieved antibody levels sufficient to enhance smoking cessation rates.
The current study investigated the combined administration of two distinct nicotine immunogens in rats as a means of enhancing the total serum NicAb response, and also reducing individual variability. The two immunogens utilized different linker positions, linker composition, and carrier proteins in order to provide distinct hapten presentations. It was hypothesized that immune responses to the two immunogens would be independent so that combining the two immunogens into a bivalent vaccine would not compromise the immune response to each individual immunogen, and would produce additive serum antibody levels. The effects of these vaccines on the distribution and serum protein binding of a single nicotine dose were also studied.
Section snippets
Immunogens
Two previously characterized nicotine immunogens were used which differ in the position and structure of the linker, and the carrier protein used (Fig. 1). 3′-Aminomethyl nicotine (3′-AmNic) was provided by Nabi Biopharmaceuticals (Boca Raton, FL) and synthesized and conjugated to recombinant Pseudomonas aeruginosa protein A (rEPA) as previously described. This immunogen has < 1% cross reactivity with the major nicotine metabolites cotinine and nicotine-N-oxide, the endogenous nicotinic
Antibody cross reactivity
Serum from rats immunized with 3′-AmNic-rEPA showed 7.6% cross reactivity when assayed with the ELISA used to quantitate antibodies elicited by 6-CMUNic-KLH. Serum from rats immunized with 6-CMUNic-KLH showed < 1% cross reactivity when assayed with the ELISA used to quantitate antibodies elicited by 3′-AmNic-rEPA.
Serum NicAb
Both immunogens elicited substantial serum antibody concentrations (Table 1). The concurrent administration of the two immunogens as a bivalent vaccine did not compromise their
Discussion
The main findings of this study were that 1) the use of nicotine haptens differing in the location and structure of the linker, as well as the carrier protein to which they are conjugated, resulted in distinct immunogens which elicited non cross-reacting antibodies, 2) the concurrent administration of these two nicotine immunogens in a bivalent vaccine did not compromise their immunogenicity, and 3) the resulting total serum antibody concentration correlated with the magnitude of vaccine
Acknowledgments
The 3′-AmNic-rEPA immunogen and rEPA carrier protein were gifts of Nabi Biopharmaceuticals. Internal standard for the nicotine assay was a gift from P Jacob (University of California, San Francisco). Supported by PHS grants DA10714, F31-DA021946, T32-DA07097, and P50-DA013333.
References (32)
- et al.
Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats
Int Immunopharmacol
(2003) - et al.
Investigations using immunization to attenuate the psychoactive effects of nicotine
Bioorg Med Chem
(2004) - et al.
Passive immunization against nicotine attenuates nicotine discrimination
Life Sci
(2002) - et al.
A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats
Pharmacol Biochem Behav
(2000) Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay
Methods of Enzymology
(1983)- et al.
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids
J Chromatog
(1981) Department of Health and Human Services. Nicotine addiction: health consequences of smoking
(1999)- et al.
Vaccines against nicotine: how effective are they likely to be in preventing smoking?
CNS Drugs
(2001) - et al.
Immunologic approaches to nicotine addiction
- et al.
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity
Eur J Immunol
(2005)
Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat
Naunyn Schmiedebergs Arch Pharmacol
Preclinical development of a vaccine ‘against smoking’
Onkologie
Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats
Psychopharmacology (Berl)
Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats
Respiration
Immunization of rats reduces nicotine distribution to brain
Psychopharmacology
Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose– and affinity–response relationships
Drug Metab Dispos
Cited by (59)
Current status of vaccines for substance use disorders: A brief review of human studies
2022, Journal of the Neurological SciencesAdvances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models
2020, NeuropharmacologyParadox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines
2018, BiomaterialsCitation Excerpt :Immunogenicity is one of the most critical factors that govern the efficacy of a nicotine vaccine [18]. The immunogenicity of a nicotine vaccine can be determined by measuring the concentrations of the nicotine-specific antibody in the animals immunized with the vaccine [19]. In both preclinical trials in animals and clinical trials in humans, it was found that a higher nicotine antibody titer in serum was associated with a better immunological outcome [20,21].
A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy
2017, Nanomedicine: Nanotechnology, Biology, and Medicine